menu
    • menu
    [{"orgOrder":0,"company":"BIOKEY","sponsor":"ABVC BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BLEX 404","moa":"||Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"BIOKEY","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BIOKEY \/ BIOKEY","highestDevelopmentStatusID":"5","companyTruncated":"BIOKEY \/ BIOKEY"},{"orgOrder":0,"company":"BIOKEY","sponsor":"NeuCen BioMed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"CEN501","moa":"Undisclosed","graph1":"Immunology","graph2":"Phase II","graph3":"BIOKEY","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Strip","sponsorNew":"BIOKEY \/ NeuCen BioMed","highestDevelopmentStatusID":"8","companyTruncated":"BIOKEY \/ NeuCen BioMed"},{"orgOrder":0,"company":"BIOKEY","sponsor":"Rgene Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"RGC-1501","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"BIOKEY","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BIOKEY \/ Rgene Corporation","highestDevelopmentStatusID":"4","companyTruncated":"BIOKEY \/ Rgene Corporation"},{"orgOrder":0,"company":"BIOKEY","sponsor":"Merdury Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"TAIWAN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"BIOKEY","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BIOKEY \/ BIOKEY","highestDevelopmentStatusID":"3","companyTruncated":"BIOKEY \/ BIOKEY"}]

    Find Clinical Drug Pipeline Developments & Deals by BIOKEY

    Menu

    BIOKEY

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BIOKEY

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            BIOKEY

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Recipient : Merdury Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            ABVC BioPharma Announces Collaboration With MerDury BioPharma for New Product Development and Commercializatio...

                            Details : The collaboration aims to develop new drug products by leveraging MerDury’s StackDose platform which has the technology to generate new products with unique fast-release properties when it is administered orally.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 06, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Recipient : Merdury Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BIOKEY

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            BIOKEY

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BLEX 404,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Recipient : ABVC BioPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Approves IND Submission Allowing ABVC BioPharma to Proceed With Clinical Study of ABV-1519 for Treatment o...

                            Details : BLEX 404, the primary active ingredient in ABV-1519, for advanced inoperable or metastatic EGFR-mutated non-small cell lung cancer has been approved and the study can proceed.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 05, 2023

                            Lead Product(s) : BLEX 404,Carboplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Recipient : ABVC BioPharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            BIOKEY

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            BIOKEY

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RGC-1501

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Rgene Corporation

                            Deal Size : $3.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ABVC BioPharma Expands Co-Development Partnership With Rgene Corporation

                            Details : BioKey has entered into a Clinical Development Service Agreement with Rgene to guide three Rgene drug products, RGC-1501 for the treatment of Non-Small Cell Lung Cancer, RGC-1502 for the treatment of pancreatic cancer and RGC 1503 for the treatment of co...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            June 21, 2022

                            Lead Product(s) : RGC-1501

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Rgene Corporation

                            Deal Size : $3.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            BIOKEY

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed

                            BIOKEY

                            U.S.A arrow
                            BOS Manchester
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CEN501

                            Therapeutic Area : Immunology

                            Study Phase : Phase II

                            Sponsor : NeuCen BioMed

                            Deal Size : $3.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            ABVC BioPharma Enters Into $3.0 Million Clinical Services Contract with NeuCen BioMed

                            Details : Under the terms of the contract, BioKey will receive payments over a 3-year period with each payment amount to be determined by certain regulatory milestones obtained in connection with CEN501 and NEU001, through completion of Phase II clinical studies.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 03, 2022

                            Lead Product(s) : CEN501

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase II

                            Sponsor : NeuCen BioMed

                            Deal Size : $3.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth